课题基金 / 基金详情

HIV-1 Integrase Structure and Function as a Therapeutic Target

HIV-1 Integrase Structure and Function as a Therapeutic Target
HIV-1 整合酶结构和功能作为治疗靶点
批准号:
7919688
负责人:
Mamuka Kvaratskhelia
金额:
$4.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-12 至 2010-08-31

项目摘要

项目成果

Mamuka Kvaratskhelia的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由候选人提供):候选人的主要目标是建立一个充满活力的,独立的研究计划集中在HIV复制复合物的结构和功能研究。这些新发现将被用来发现新的有效的抗逆转录病毒抑制剂。自2003年8月以来,候选人一直在俄亥俄州州立大学(OSU)药学院担任助理教授。该研究目前得到了以下两项NIH赠款:R 01-“HIV-1整合的结构研究”和R21 -“HIV-1 Gag结构作为治疗靶点”。在候选人职业生涯的这个阶段,独立科学家奖(伊萨)将极大地帮助他专注于他的研究工作。候选人在本学年的教学工作量包括指导本科生、专业学生和研究生60次讲座和120小时的实验室课程。这些非常重要的教学责任减缓了候选人的研究活动。如果获得伊萨,大学将把候选人的教学负担降低到-15%的努力水平。候选人的研究计划将大大受益于这减少课程负担。他将有时间自己从事实验室工作,并直接指导他的博士后研究员和研究生。候选人将参加科学会议和讲习班,以增进他在计划今后从事的领域的知识,并与该领域的其他科学家进行更密切的互动。俄勒冈州立大学的设施和研究环境也有利于实现既定目标。该候选人目前的研究活动旨在阐明HIV-1 IN如何与同源核酸和细胞辅因子相互作用,并确定抑制这些功能性相互作用的新小分子。HIV-1 IN通常被视为重要的治疗靶点,原因如下:IN的催化活性是病毒复制所必需的,IN没有密切相关的细胞等效物,特异性IN抑制剂可能对目前可用的靶向逆转录酶、蛋白酶和融合的治疗耐药的病毒株有效。详细的结构和机制信息的功能HIV-1 IN核蛋白复合物可以帮助药物设计的努力。候选人的研究小组正在使用创新的生物化学/生物物理方法解决这些重要问题,包括候选人实验室开发的质谱蛋白质足迹技术。
英文摘要
DESCRIPTION (provided by candidate): The candidate's main objective is to establish a vigorous, independent research program centered on structure and function studies of HIV replication complexes. The new findings will be exploited to discover novel effective antiretroviral inhibitors. Since August of 2003 the candidate has been Assistant Professor at the Ohio State University (OSU) College of Pharmacy. The candidate's research is currently supported by the following two NIH grants: R01 - "structural studies of HIV-1 integration" and R21 - "HIV-1 Gag structure as a therapeutic target". An Independent Scientist Award (ISA) at this stage of the candidate's career would help him enormously to focus on his research endeavors. The candidate's teaching load for the current academic year includes instructing undergraduate, professional and graduate students 60 lectures and 120 hrs laboratory courses. These very significant teaching responsibilities slow down the candidate's research activities. If awarded an ISA, the University will reduce the candidate's teaching load to an -15% effort level. The candidate's research program would benefit greatly from this reduced course load. He would have time to pursue the lab work himself and directly supervise his postdoctoral fellow and graduate students. The candidate would attend scientific meetings and workshops to enhance his knowledge in the areas that he plans to pursue in future and more closely interact with other scientists in the field. The facilities and research environment at OSU are also conducive to the stated goals. The candidate's current research activities aim to elucidate how HIV-1 IN interacts with cognate nucleic acids and cellular cofactors, and identify new small molecules inhibiting these functionally essential interactions. HIV-1 IN is commonly viewed as an important therapeutic target for the following reasons: catalytic activities of IN are required for viral replication, there is no closely related cellular equivalent of IN, and specific IN inhibitors are likely to be effective against viral strains resistant to currently available therapies targeting reverse transcriptase, protease, and fusion. Detailed structural and mechanistic information on functional HIV-1 IN nucleoprotein complexes could aid drug design efforts. The candidate's research group is addressing these important problems using innovative biochemical/biophysical approaches including mass spectrometric protein footprinting technologies developed in the candidate's laboratory.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Imaging early steps of HIV-1 infection and virus-host factor interactions
  • 批准号:
    10548587
  • 项目类别:
  • 资助金额:
    $58.21万
  • 财政年份:
    2022
  • 负责人:
    Mamuka Kvaratskhelia
  • 依托单位:
Imaging early steps of HIV-1 infection and virus-host factor interactions
  • 批准号:
    10646359
  • 项目类别:
  • 资助金额:
    $56.64万
  • 财政年份:
    2022
  • 负责人:
    Mamuka Kvaratskhelia
  • 依托单位:
Multimeric HIV-1 Integrase Inhibitors
  • 批准号:
    10570935
  • 项目类别:
  • 资助金额:
    $49.82万
  • 财政年份:
    2019
  • 负责人:
    Mamuka Kvaratskhelia
  • 依托单位:
Multimeric HIV-1 Integrase Inhibitors
  • 批准号:
    10348747
  • 项目类别:
  • 资助金额:
    $49.95万
  • 财政年份:
    2019
  • 负责人:
    Mamuka Kvaratskhelia
  • 依托单位:
海外基金